The FDA has approved Trulicity (dulaglutide; Lilly) to reduce the risk of major adverse cardiovascular events (MACE; cardiovascular death, nonfatal myocardial infarction [MI], or nonfatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
The FDA has approved Anjeso (meloxicam injection; Baudax Bio) for the management of moderate to severe pain, alone or in combination with NSAIDs in adult patients.
Among systemic treatments for plaque psoriasis, brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were found to be associated with the highest Psoriasis Area and Severity Index (PASI) response rates.
Clinicians should discuss alternative weight-loss medications and strategies with patients.
A recent systematic review identified several established as well as emerging practices utilized in the pediatric setting that were associated with overuse of medical care.
Higher doses anti-tumor necrosis factor-α (anti-TNF-α) therapy may be neceessary for obese patients with ulcerative colitis (UC), according to the findings of a recently published meta-analysis.
Yesterday, the World Health Organization gave the virus a new name: COVID-19.
Behavioral strategies recommended as first-line treatment approach for children, teens with ASD
The FDA has granted 510(k) clearance to the Hyperfine system (Hyperfine Research), a bedside magnetic resonance imaging (MRI) system.
Linagliptin was not associated with an increased risk of adverse cardiovascular (CV) events, renal events or hypoglycemia in older patients with type 2 diabetes, according to subgroup analysis from the phase 4 Carmelina® trial.
Please login or register first to view this content.
